Shilpa Medicare Limited Stock Price Today (NSE: SHILPAMED)
Fundamental Score
Shilpa Medicare Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Shilpa Medicare Limited share price today is ₹928.05, up +1.77% on NSE/BSE as of 16 September 2026. Shilpa Medicare Limited (SHILPAMED) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹9.28 (Cr). The 52-week high for SHILPAMED share price is ₹980.10 and the 52-week low is ₹259.50. At a P/E ratio of 60.74x, SHILPAMED is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 9.80% and a debt-to-equity ratio of 0.25.
Shilpa Medicare Limited Share Price Chart — NSE/BSE Historical Performance
Shilpa Medicare Limited share price chart: 18.95% return over the past month. 52-week high ₹980.10, 52-week low ₹259.50.
Shilpa Medicare Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹909.90 | ₹945.00 | ₹874.85 | ₹928.05 | 11.87L (Cr) | |
| ₹968.00 | ₹968.75 | ₹902.25 | ₹911.90 | 7.57L (Cr) | |
| ₹935.00 | ₹975.00 | ₹910.00 | ₹961.15 | 14.72L (Cr) | |
| ₹968.95 | ₹974.00 | ₹931.30 | ₹939.90 | 6.83L (Cr) | |
| ₹959.90 | ₹974.95 | ₹954.10 | ₹960.60 | 6.95L (Cr) | |
| ₹949.85 | ₹965.00 | ₹937.10 | ₹959.90 | 7.15L (Cr) | |
| ₹974.00 | ₹980.10 | ₹923.00 | ₹939.50 | 10.88L (Cr) | |
| ₹956.15 | ₹973.90 | ₹946.20 | ₹964.15 | 6.53L (Cr) | |
| ₹935.00 | ₹966.45 | ₹923.60 | ₹956.15 | 18.65L (Cr) | |
| ₹889.00 | ₹930.85 | ₹887.05 | ₹928.55 | 14.65L (Cr) |
Shilpa Medicare Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹950.00 | ₹980.10 | ₹874.00 | ₹928.05 | -2.31% | |
| ₹616.10 | ₹950.00 | ₹614.10 | ₹949.30 | +54.08% | |
| ₹588.00 | ₹650.00 | ₹561.50 | ₹611.25 | +3.95% | |
| ₹504.50 | ₹615.00 | ₹493.40 | ₹598.40 | +18.61% | |
| ₹406.65 | ₹529.80 | ₹406.65 | ₹498.95 | +22.70% | |
| ₹360.00 | ₹436.40 | ₹350.60 | ₹406.65 | +12.96% | |
| ₹315.90 | ₹365.00 | ₹308.30 | ₹348.90 | +10.45% | |
| ₹288.00 | ₹350.90 | ₹272.00 | ₹336.65 | +16.89% | |
| ₹320.00 | ₹324.55 | ₹259.50 | ₹288.95 | -9.70% | |
| ₹343.20 | ₹353.45 | ₹313.15 | ₹321.15 | -6.42% | |
| ₹357.30 | ₹415.00 | ₹340.00 | ₹341.50 | -4.42% | |
| ₹380.00 | ₹407.70 | ₹342.00 | ₹352.85 | -7.14% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Shilpa Medicare Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Shilpa Medicare Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SHILPAMED across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (21.08%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (147.82%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (44.90%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (13.13% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.25)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (6.02x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Risk Factors
4 factors identified
Below-Average Return on Equity (9.80%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 60.74x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-11.27% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-461.23 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Shilpa Medicare Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Shilpa Medicare Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Shilpa Medicare LimitedShilpa Medicare...Selected✓ SHILPAMED • 530549 | 53.2/100 | ₹928.05₹928 | ₹9.28₹9.28 | 60.74Average 60.7 Average | 9.80%Poor 9.80% Poor | 12.89%Average 12.89% Average | 0.25Excellent 0.3 Excellent | 5.70%Good 5.70% Good | 13.13%Good 13.13% Good | 0.08% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Shilpa Medicare Limited PE Ratio History
Historical price-to-earnings ratio for SHILPAMED — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹8.04 | ₹321.15 | 39.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Shilpa Medicare Limited Dividend History
Annual cash dividends paid by SHILPAMED — dividend yield 0.08%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2023 | ₹9.55 Cr |
| FY 2022 | ₹8.97 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Shilpa Medicare Limited Quarterly Performance
Latest quarterly metrics for SHILPAMED — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
44.90%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
147.82%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.13%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
5.70%
Compounded annual net profit growth over 5 years
Shilpa Medicare Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SHILPAMED — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Shilpa Medicare Limited Financial Statements
Annual income statement, balance sheet and cash flow for Shilpa Medicare Limited (SHILPAMED) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Shilpa Medicare Limited
About SHILPAMED (Shilpa Medicare Limited)
Shilpa Medicare Ltd is a global pharmaceutical company with a prominent footprint in oncology and specialty therapeutics. The company distinguishes itself through its comprehensive... range of capabilities, encompassing the entire pharmaceutical value chain, from the development and manufacture of active pharmaceutical ingredients (APIs) to the production of finished dosage formulations and innovative biosimilars. Shilpa Medicare focuses on cutting-edge research and development, aiming to provide high-quality, affordable medicines that address unmet medical needs across a diverse range of therapeutic areas. It emphasizes sustainable practices and aims to adhere to global regulatory standards in all aspects of its operations. Shilpa Medicare operates through diverse divisions, including API manufacturing, formulations production, and biosimilar development. Its API portfolio includes a wide array of both oncology and non-oncology ingredients, catering to the requirements of pharmaceutical companies across the globe. The company's finished dosage formulation unit produces a broad spectrum of therapeutic options, while its biosimilars division is focused on developing and commercializing cost-effective alternatives to complex biologic drugs. Shilpa Medicare strategically invests in advanced technology and infrastructure to support its manufacturing activities and ensures consistent product quality and reliability. Shilpa Medicare's commercial presence spans across multiple continents, with a dedicated focus on expanding its reach in key markets such as India, the United States, and Europe. The company fosters strategic partnerships and collaborations to accelerate its growth and strengthen its market position. By integrating technological advancements, scientific expertise, and a strong focus on customer satisfaction, Shilpa Medicare strives to contribute significantly to the advancement of healthcare worldwide. It aims to continuously innovate and improve its products and services to meet the evolving needs of patients and healthcare providers.
Company Details
Key Leadership
SHILPAMED Share Price: Frequently Asked Questions
What is the current share price of Shilpa Medicare Limited?
Shilpa Medicare Limited (SHILPAMED) trades at ₹928.05 on NSE and BSE. Market cap ₹9.28 (Cr). Educational data only.
What is the P/E ratio of Shilpa Medicare Limited?
Shilpa Medicare Limited has a P/E of 60.74x vs industry average 34.89x.
What is the Bull Run score for Shilpa Medicare Limited?
Shilpa Medicare Limited has a Bull Run score of 53.2/100 based on 25+ financial parameters.
Does Shilpa Medicare Limited pay dividends?
Shilpa Medicare Limited has a dividend yield of 0.08%. Past dividends don't guarantee future payments.
What is the ROE of Shilpa Medicare Limited?
Shilpa Medicare Limited has ROE of 9.80%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Shilpa Medicare Limited?
Shilpa Medicare Limited has debt-to-equity of 0.25.
Is Shilpa Medicare Limited a good investment?
Bull Run gives Shilpa Medicare Limited a score of 53.2/100. This is not investment advice — consult a SEBI-registered advisor.